REGENXBIO INC (RGNX) — insider trading
Health Care · NASDAQ
REGENXBIO INC (RGNX) has 37 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases and 4 open-market sales among the most recent 37 (latest 2026-09-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | Chan Mitchell | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 4,902 | $9.32 | $45.7K | Form 4 |
| 2026-09-01 | Malzahn Craig | Officer (Chief Technology Officer) | Shares withheld for taxes / exercise cost | 234 | $9.32 | $2.2K | Form 4 |
| 2026-08-27 | Ciongoli Gregory Austin | Director | Open-market purchase | 53,407 | $9.36 | $499.7K | Form 4 |
| 2026-08-26 | Ciongoli Gregory Austin | Director | Open-market purchase | 49,196 | $9.14 | $449.7K | Form 4 |
| 2026-08-25 | Ciongoli Gregory Austin | Director | Grant / award / vesting (derivative) | 69,609 | — | $0 | Form 4 |
| 2026-08-25 | Ciongoli Gregory Austin | Director | Grant / award / vesting | 15,432 | — | $0 | Form 4 |
| 2026-08-01 | Christmas Patrick J. | Officer (Chief Strategy & Legal Officer) | Shares withheld for taxes / exercise cost | 4,699 | $9.69 | $45.5K | Form 4 |
| 2026-08-01 | PAKOLA STEVE | Officer (Chief Medical Officer) | Shares withheld for taxes / exercise cost | 7,468 | $9.69 | $72.4K | Form 4 |
| 2026-07-02 | PAKOLA STEVE | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 2,161 | — | $0 | Form 4 |
| 2026-07-02 | PAKOLA STEVE | Officer (Chief Medical Officer) | Open-market sale | 2,161 | $13.64 | $29.5K | Form 4 |
| 2026-07-02 | PAKOLA STEVE | Officer (Chief Medical Officer) | Option exercise / conversion | 2,161 | $7.86 | $17.0K | Form 4 |
| 2026-07-01 | Simpson Curran | Director, Officer (Chief Executive Officer) | Shares withheld for taxes / exercise cost | 6,818 | $13.09 | $89.2K | Form 4 |
| 2026-07-01 | PAKOLA STEVE | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 36,725 | — | $0 | Form 4 |
| 2026-07-01 | PAKOLA STEVE | Officer (Chief Medical Officer) | Open-market sale | 36,725 | $12.86 | $472.3K | Form 4 |
| 2026-07-01 | PAKOLA STEVE | Officer (Chief Medical Officer) | Option exercise / conversion | 36,725 | $7.86 | $288.7K | Form 4 |
| 2026-06-30 | Simpson Curran | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 1,453 | $10.18 | $14.8K | Form 4 |
| 2026-06-29 | PAKOLA STEVE | Officer (Chief Medical Officer) | Open-market sale | 19,608 | $11.04 | $216.5K | Form 4 |
| 2026-05-29 | Bennett Jean | Director | Grant / award / vesting (derivative) | 46,600 | — | $0 | Form 4 |
| 2026-05-29 | Bennett Jean | Director | Grant / award / vesting | 9,807 | — | $0 | Form 4 |
| 2026-05-29 | Fox Allan M. | Director | Grant / award / vesting (derivative) | 46,600 | — | $0 | Form 4 |
| 2026-05-29 | Fox Allan M. | Director | Grant / award / vesting | 9,807 | — | $0 | Form 4 |
| 2026-05-29 | Glucksmann Alexandra | Director | Grant / award / vesting (derivative) | 46,600 | — | $0 | Form 4 |
| 2026-05-29 | Glucksmann Alexandra | Director | Grant / award / vesting | 9,807 | — | $0 | Form 4 |
| 2026-05-29 | KARABELAS ARGERIS N | Director | Grant / award / vesting (derivative) | 46,600 | — | $0 | Form 4 |
| 2026-05-29 | KARABELAS ARGERIS N | Director | Grant / award / vesting | 9,807 | — | $0 | Form 4 |
| 2026-05-29 | MIGAUSKY GEORGE V | Director | Grant / award / vesting (derivative) | 46,600 | — | $0 | Form 4 |
| 2026-05-29 | MIGAUSKY GEORGE V | Director | Grant / award / vesting | 9,807 | — | $0 | Form 4 |
| 2026-05-29 | Mills Kenneth T. | Director | Grant / award / vesting (derivative) | 46,600 | — | $0 | Form 4 |
| 2026-05-29 | Mills Kenneth T. | Director | Grant / award / vesting | 9,807 | — | $0 | Form 4 |
| 2026-05-29 | Zachary Jennifer | Director | Grant / award / vesting (derivative) | 46,600 | — | $0 | Form 4 |
| 2026-05-29 | Zachary Jennifer | Director | Grant / award / vesting | 9,807 | — | $0 | Form 4 |
| 2026-05-29 | STUMP DAVID C | Director | Grant / award / vesting (derivative) | 46,600 | — | $0 | Form 4 |
| 2026-05-29 | STUMP DAVID C | Director | Grant / award / vesting | 9,807 | — | $0 | Form 4 |
| 2026-05-29 | Tasse Daniel | Director | Grant / award / vesting (derivative) | 46,600 | — | $0 | Form 4 |
| 2026-05-29 | Tasse Daniel | Director | Grant / award / vesting | 9,807 | — | $0 | Form 4 |
| 2026-05-11 | PAKOLA STEVE | Officer (Chief Medical Officer) | Open-market sale | 15,309 | $11.02 | $168.7K | Form 4 |
| 2025-12-31 | Simpson Curran | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 951 | $7.00 | $6.7K | Form 4 |
Ask the chat about RGNX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: REGENXBIO INC (RGNX).
Last updated 2026-09-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.